The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Rosenlund L, Guldbrandsen K, Ahlborn LB, Bloch M, Skougaard K, Albrecht-Beste E, Nellemann HM, Krakauer M, Gørtz PM, Fledelius J, Nielsen AL, Holdgaard PC, Nielsen SS, Grüner JM, Højsgaard A, Petersen RH, Møller LB, Dahl M, Frank MS, Ehlers JH, Saghir Z, Pøhl M, Borissova S, Land LH, Kristiansen C, McCulloch T, Mortensen LS, Christophersen MS, Hilberg O, Rasmussen TL, Simonsen Schwaner SH, Laursen CB, Bodtger U, Lonsdale MN, Meyer CN, Gerke O, Mortensen J, Rasmussen TR, Hjorthaug K, Larsen KR, Meldgaard P, Fischer BM, Sorensen BS

doi: 10.1016/j.lungcan.2025.108528

Lung, Respiratory and Thoracic Cancer

Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer

Clin Cancer Res

Provencio M, Serna-Blasco R, Nadal E, González Larriba JL, Martinez-Marti A, Bernabé Caro R, Bosch-Barrera J, Calvo V, Insa Molla A, Reguart N, de Castro Carpeño J, Aguado de la Rosa C, Palmero Sanchez R, Hernando Trancho F, Martín-López J, Rodríguez-Festa A, Mediavilla-Medel P, Lázaro M, Hayes J, Cruz-Bermúdez A, Massutí B, Romero A

doi: 10.1158/1078-0432.CCR-25-2958

Gynecologic Cancer

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Ann Oncol

Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, Leiva M, Cetina-Pérez LDC, Varga S, Molina Alavez A, Alarcon-Rozas AE, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Shapira-Frommer R, Estevez-Diz MDP, Limaye S, Xin W, Dry H, Broggi MAS, Yuan DY, Stewart RA, Monk BJ

doi: 10.1016/j.annonc.2025.05.533

Multiple Myeloma (MM)

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Haematologica

Yoroidaka T, Takamatsu H, Urushihara R, Itagaki M, Yoshihara S, Sato K, Takezako N, Ozaki S, Suzuki K, Kohno K, Muta T, Matsumoto M, Terasaki Y, Yamashita T, Fuchida SI, Sakamoto J, Ishida T, Suzuki K, Murakami H, Durie BGM, Shimizu K

doi: 10.3324/haematol.2025.287411

Further Publications

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Ann Oncol

Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G

doi: 10.1016/j.annonc.2025.03.019

Lymphoma

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

J Clin Oncol

Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED

doi: 10.1200/JCO-25-01712

Head and Neck Cancer

Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer

Clin Cancer Res

Sim ES, Rhoades J, Xiong K, Walsh L, Crnjac A, Blewett T, Al-Inaya Y, Mendel J, Ruiz-Torres DA, Efthymiou V, Lumaj G, Benjamin WJ, Makrigiorgos GM, Tabrizi S, Adalsteinsson VA, Faden DL

doi: 10.1158/1078-0432.CCR-25-0307

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Skin Cancer

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Ann Oncol

Rawson RV, Maher NG, Menzies AM, Lo SN, Ardakani NM, Jackett LA, Vergara IA, Pennington TE, Shannon KF, Ch'ng S, Gonzalez M, Burton EM, Lucas MW, Reijers ILM, Rozeman EA, Gyorki DE, Sandhu S, Carlino MS, Howle J, Khattak M, Van der Westhuizen A, Andrews MC, Atkinson V, van Akkooi ACJ, Spillane AJ, Saw RPM, van de Wiel BA, Blank CU, Long GV, Tetzlaff MT, Scolyer RA

doi: 10.1016/j.annonc.2025.10.1237

Related content

ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach

Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma